Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Kuros Biosciences News

    6,89 CHF +2,38% +0,16 CHF
    In : 7,0397 € | 17:31:57 Uhr SIX Swiss Exchange aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2ALS5
    ISIN: CH0325814116
    US-Symbol: CSBTF
    Typ: Aktie

    Ad-hocs

    24.04.24 - DGAP
    Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
    Kuros Biosciences AG / Key word(s): Quarter Results/Regulatory Approval Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales 24-Apr-...
    13.03.24 - DGAP
    Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
    Kuros Biosciences AG / Key word(s): Annual Results Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023 13-...
    27.12.23 - DGAP
    Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
    Kuros Biosciences AG / Key word(s): Study/Study results Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA 27-Dec-...
    12.10.23 - DGAP
    Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
    Kuros Biosciences AG / Key word(s): Quarter Results Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the ...
    09.08.23 - DGAP
    Kuros Biosciences Reports Results for First Half 2023
    Kuros Biosciences AG / Key word(s): Half Year Results Kuros Biosciences Reports Results for First Half 2023 09-Aug-2023 / 07:00 CET/CEST Release of an ad hoc announcement ...
    08.05.23 - DGAP
    Annual General Meeting of Kuros Biosciences approves all resolutions
    Kuros Biosciences AG / Key word(s): Miscellaneous Annual General Meeting of Kuros Biosciences approves all resolutions 08-May-2023 / 17:18 CET/CEST Release of an ad hoc ...
    27.04.23 - DGAP
    Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023 27-Apr-2023 / 07:00 CET/CEST Release of an ...
    15.03.23 - DGAP
    Kuros Biosciences reports results for the full year 2022
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences reports results for the full year 2022 15-March-2023 / 07:00 CET/CEST Release of an ad hoc announcement ...
    16.02.23 - DGAP
    Kuros Biosciences Announces Changes to Executive Management Team
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Announces Changes to Executive Management Team 16-Feb-2023 / 18:01 CET/CEST Release of an ad hoc ...
    26.10.22 - DGAP
    Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros reports 73% increase in MagnetOs sales in first nine months of 2022 26-Oct-2022 / 07:00 CET/CEST Release of an ad ...
    03.10.22 - DGAP
    Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Appoints Chris Fair as Chief Operating Officer 03-Oct-2022 / 07:00 CET/CEST Release of an ad hoc ...
    15.09.22 - DGAP
    Kuros Biosciences announces successful CHF 6.0 million private placement
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences announces successful CHF 6.0 million private placement 15-Sep-2022 / 07:00 CET/CEST Release of an ad ...
    09.08.22 - DGAP
    Kuros Biosciences reports results for the first six months of 2022
    Kuros Biosciences AG / Key word(s): Half Year Results Kuros Biosciences reports results for the first six months of 2022 09-Aug-2022 / 17:50 CET/CEST Release of an ad hoc ...
    08.06.22 - DGAP
    Annual General Meeting of Kuros Biosciences approves all resolutions
    Kuros Biosciences AG / Key word(s): AGMEGM Annual General Meeting of Kuros Biosciences approves all resolutions 08-Jun-2022 / 19:00 CET/CEST Release of an ad hoc ...
    02.06.22 - DGAP
    Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 ...
    27.04.22 - DGAP
    Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
    Kuros Biosciences AG / Key word(s): Quarter Results Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft 27-Apr-2022 / 08:07 CET/CEST Release of ...
    21.04.22 - DGAP
    Kuros Biosciences's MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences's MagnetOs Flex Matrix Cleared by FDA for Spinal Indications 21-Apr-2022 / 07:00 CET/CEST Release of an ...
    16.03.22 - DGAP
    Kuros Biosciences reports results for the full year 2021
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences reports results for the full year 2021 16-March-2022 / 07:00 CET/CEST Release of an ad hoc announcement ...
    26.10.21 - DGAP
    EQS-Adhoc: Kuros Biosciences reports continued increase in MagnetOs U.S. sales
    EQS Group-​Ad-hoc: Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences reports continued increase in MagnetOs U.S. sales 26-Oct-2021 / 07:00 CET/CEST ...
    11.08.21 - DGAP
    EQS-Adhoc: Kuros Biosciences Reports Results for First Half 2021
    EQS Group-​Ad-hoc: Kuros Biosciences AG / Key word(s): Half Year Results Kuros Biosciences Reports Results for First Half 2021 11-Aug-2021 / 07:00 CET/CEST Release of an ad ...

    Newssuche

    Videos

    newspaper
    09:30 Uhr +21,95%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »